Population Pharmacokinetic Analysis for Imipenem-Relebactam in Healthy Volunteers and Patients With Bacterial Infections

• Egile Nagusiak: Pratik Bhagunde (Egilea), Parul Patel (Egilea), Mallika Lala (Egilea), Kenny Watson (Egilea), William Copalu (Egilea), Ming Xu (Egilea), Pooja Kulkarni (Egilea), Katherine Young (Egilea), Matthew L. Rizk (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2019-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Relebactam is a small‐molecule β‐lactamase inhibitor developed as a fixed‐dose combination with imipenem/cilastatin. The pharmacokinetics of relebactam and imipenem across 10 clinical studies were analyzed using data from adult healthy volunteers and patients with bacterial infections. Renal functio...